Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Thursday, possibly on profit-taking after the stock rallied roughly 10% on Wednesday.
On Wednesday, Eli Lilly reported fourth-quarter adjusted earnings of $7.54 per share, beating the consensus of $6.67.
The company’s sales reached $19.3 billion, beating the consensus of $17.96 billion.
The obesity drug maker expects sales between $80 billion-$83 billion compared to the Wall Street estimate of $77.62 billion.
Eli Lilly sees fiscal 2026 adjusted earnings of $33.50-$35 per share compared to the consensus of $33.23.
Analyst View
Cantor, in an investor note, wrote that Eli Lilly’s fiscal 2026 guidance was a strong rebuttal to concerns over GLP-1 pricing or demand.
Cantor analyst Carter Gould maintains the Overweight rating with a price forecast of $1,205, up from $985, reflecting portfolio momentum and a more favorable backdrop for biopharma.
The analyst says their topline estimate of around $82 billion for fiscal 2026 implies incretin sales of approximately $57 billion, a step up of around $16 billion over fiscal 2025, with a mere $1 billion contribution from Orforglipron.
“We expect the stock direction to be driven by the evolution of orforglipron prescription (which investors expect to launch early next quarter). Though there are encouragingly clear sources of upside to numbers that don’t involve the U.S. orforglipron ramp, we think those are less relevant if the orforglipron prescription ramp is less persuasive.”
Cantor expects over 3 million orforglipron prescriptions in fiscal 2026, an estimate that analyst Carter says is reasonable given the partial year, medicare access in mid-year, and lack of cannibalization.
LLY Price Action: Eli Lilly and Co shares were down 6.47% at $1035.50 at the time of publication on Thursday, according to Benzinga Pro data.
Photo by M7kk via Shutterstock
Recent Comments